Management of Hypertension and Atrial Fibrillation

Rate Control and Blood Pressure Management

• The American College of Cardiology recommends beta-blockers or non-dihydropyridine calcium channel antagonists as first-line agents for rate control in atrial fibrillation, with beta-blockers being the preferred choice for controlling both heart rate and blood pressure without the risk of peripheral edema 1, 2.
• Beta-blockers such as metoprolol or carvedilol are reasonable choices for rate control in atrial fibrillation, with a recommended starting dose of 25-50mg daily and titration based on heart rate and blood pressure response 1, 2.
• The combination of an angiotensin receptor blocker (ARB) like valsartan with a beta-blocker is rational and effective for hypertension management, particularly in elderly patients with atrial fibrillation 6, 7.

Stroke Prevention

• The American College of Cardiology recommends anticoagulation with a vitamin K antagonist (warfarin, INR 2.0-3.0) or a direct oral anticoagulant for patients with more than one moderate risk factor for stroke, with a high risk of stroke defined as an annual risk of 5-7% or higher 1, 3, 4, 5.
• Blood pressure must be strictly controlled when anticoagulation is initiated, with a target blood pressure of <140/90 mmHg to minimize bleeding risk 6, 5.

Monitoring and Follow-up

• The American College of Cardiology recommends monitoring heart rate at rest and assessing adequacy during activity, adjusting pharmacological treatment to keep rate in physiological range 1, 2.
• Renal function and electrolytes, particularly potassium, should be monitored closely in elderly patients on ARBs and diuretics, with regular checks of INR for patients on warfarin 8, 1, 3.

Common Pitfalls to Avoid

• The American College of Cardiology advises against using digoxin as the sole agent for rate control in atrial fibrillation, and against delaying anticoagulation in patients with a high risk of stroke 1, 2, 3, 4, 5.
• Non-dihydropyridine calcium channel antagonists should be avoided in patients with heart failure, as they can worsen hemodynamics 1, 2, 3.